Breakthrough Drug Kisqali Offers New Hope for Breast Cancer Patients, Significantly Extends Survival
Table of Contents
A novel treatment is offering a significant advancement in the fight against the most common form of breast cancer. Ribociclib, marketed as Kisqali®, has demonstrated unprecedented effectiveness in halting disease progression, even in advanced stages, offering renewed hope to patients and transforming expectations for long-term survival.
The findings, recently presented at the prestigious San Antonio Breast Cancer Symposium® (SABCS), are particularly impactful for those diagnosed with HR+/HER2− breast cancer, a subtype representing approximately 70% of all breast tumor cases. This form of the disease is characterized by hormone receptor positivity and the absence of HER2 protein overexpression.
Unprecedented Results in Advanced Disease
Analysis of long-term data from the MONALEESA study reveals that Kisqali, when used in combination with endocrine therapy as a first-line treatment, allows one in four patients to remain free of tumor progression for four years or more. This is a remarkable outcome for patients facing a challenging diagnosis.
Further analysis indicates the benefit remains consistent regardless of a patient’s menopausal status or the presence of factors typically associated with a poorer prognosis, such as liver metastases. Patients treated with Kisqali achieved a median progression-free survival of 6.8 years – a figure that dramatically alters the outlook for individuals with advanced disease. According to a company release, the treatment has also demonstrated an increase in overall survival across three phase III studies.
“Our biomarker analyses demonstrate clinical and genomic factors potentially associated with these extraordinary responses, highlighting the importance of precision medicine to identify which patients can obtain the greatest benefit,” stated a leading oncologist at Memorial Sloan Kettering Cancer Center. A senior official at Novartis, the pharmaceutical company that developed Kisqali, added that the drug “continues to fulfill its promise of providing a potential benefit in the lifespan of people living with advanced breast cancer.”
Reducing the Risk of Relapse in Early-Stage Breast Cancer
The positive impact of Kisqali extends beyond advanced disease. The drug is also proving to be a crucial tool in reducing the risk of relapse in early-stage breast cancer – a critical challenge, as the disease can reappear years later, often as metastasis, when curative options are limited.
A five-year subanalysis of the NATALEE study confirmed that ribociclib, combined with an aromatase inhibitor, significantly improves distant disease-free survival. Specifically, the treatment reduces the risk of invasive relapse by 28% over five years and lowers the risk of distant relapse (metastasis) by 30%. Importantly, this benefit persists even after therapy is completed.
“It is especially relevant that the therapy has demonstrated a consistent and clinically significant benefit in all patient profiles in the study, including those without lymph node involvement,” highlighted a medical oncologist at the Arnau Hospital of Vilanova in Valencia.
Spain’s Key Role in Groundbreaking Research
The Spanish scientific community has played a pivotal role in this medical advancement. Spain was the second highest participating country in the NATALEE study, trailing only the United States. A total of 47 hospitals across 12 autonomous communities, coordinated by the GEICAM Breast Cancer Research Group, contributed data from 761 patients – nearly 15% of the global total.
A president of the Spanish Cancer Research Association (ASEICA) emphasized that, even with these advances, a significant probability of relapse remains in high-risk cases, potentially reaching 30%. However, he also underscored the drug’s “good tolerance and for allowing dose adjustments without losing effectiveness, which facilitates adherence and quality of life.”
This breakthrough, therefore, holds the potential to fundamentally change the prognosis for a substantial number of women facing a breast cancer diagnosis.
